SCHEMBL3670306

SCHEMBL3670306

Cc1nc(-c2ccc3[nH]ncc3c2)cs1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 7/20 1.00
AURKB Q96GD4 7/20 1.00
GSK3B P49841 7/20 1.00
PIM1 P11309 5/20 1.00
CLK2 P49760 3/20 0.59
DYRK1A Q13627 3/20 0.59
CLK4 Q9HAZ1 3/20 0.59
RPS6KB1 P23443 2/20 0.59
CDK2 P24941 2/20 0.59
GSK3A P49840 2/20 0.59
ROCK1 Q13464 2/20 0.59
PKN2 Q16513 2/20 0.59
BRSK1 Q8TDC3 2/20 0.59
MKNK2 Q9HBH9 2/20 0.59
STK17A Q9UEE5 2/20 0.59
KDR P35968 2/20 0.59
DYRK3 O43781 2/20 0.59
PRKD3 O94806 1/20 0.59
MAP4K4 O95819 1/20 0.59
ROS1 P08922 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3668053 0.83 ROCK2 (1.00) ROCK2AURKBGSK3BPIM1CLK2
SCHEMBL9093554 0.78 ROCK2 (0.64) ROCK2AURKBGSK3BPIM1MAPT
SCHEMBL3668478 0.78 AURKB (1.00) ROCK2AURKBGSK3BPIM1CLK2
SCHEMBL13680617 0.76 GSK3B (0.61) ROCK2AURKBGSK3BPIM1CLK2
SCHEMBL3637752 0.74 ROCK2 (1.00) ROCK2AURKBGSK3BPIM1CLK2
SCHEMBL13680563 0.74 TGFBR1 (0.77) ROCK2AURKBGSK3BPIM1CLK2
SCHEMBL16573980 0.74 GSK3B (0.71) ROCK2AURKBGSK3BPIM1CLK2
SCHEMBL2461778 0.73 GSK3B (0.59) ROCK2AURKBGSK3BPIM1CLK2
SCHEMBL19626747 0.73 CDC25A (0.58) ROCK2AURKBGSK3BPIM1MAPT
SCHEMBL15344157 0.73 GSK3B (0.57) ROCK2AURKBGSK3BPIM1CLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 ROCK2 48/4885AURKB 125/4885GSK3B 1/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 ROCK2 48/4885AURKB 125/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.